COMPUGROUP MEDICAL SE & CO K (COP.DE) Fundamental Analysis & Valuation

FRA:COP • DE000A288904

Current stock price

22.66 EUR
+0.24 (+1.07%)
Last:

This COP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. COP.DE Profitability Analysis

1.1 Basic Checks

  • COP had positive earnings in the past year.
  • In the past year COP had a positive cash flow from operations.
  • Each year in the past 5 years COP has been profitable.
  • In the past 5 years COP always reported a positive cash flow from operatings.
COP.DE Yearly Net Income VS EBIT VS OCF VS FCFCOP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 1.34%, COP is in line with its industry, outperforming 50.00% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 4.15%, COP is in line with its industry, outperforming 50.00% of the companies in the same industry.
  • The Return On Invested Capital of COP (3.53%) is worse than 60.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for COP is below the industry average of 8.00%.
Industry RankSector Rank
ROA 1.34%
ROE 4.15%
ROIC 3.53%
ROA(3y)2.65%
ROA(5y)3.3%
ROE(3y)7.71%
ROE(5y)9.17%
ROIC(3y)4.07%
ROIC(5y)4.45%
COP.DE Yearly ROA, ROE, ROICCOP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • Looking at the Profit Margin, with a value of 2.34%, COP is in line with its industry, outperforming 50.00% of the companies in the same industry.
  • COP's Profit Margin has declined in the last couple of years.
  • COP's Operating Margin of 8.13% is in line compared to the rest of the industry. COP outperforms 60.00% of its industry peers.
  • COP's Operating Margin has declined in the last couple of years.
  • With a decent Gross Margin value of 83.85%, COP is doing good in the industry, outperforming 70.00% of the companies in the same industry.
  • In the last couple of years the Gross Margin of COP has grown nicely.
Industry RankSector Rank
OM 8.13%
PM (TTM) 2.34%
GM 83.85%
OM growth 3Y-2.61%
OM growth 5Y-10.29%
PM growth 3Y-23.61%
PM growth 5Y-19.42%
GM growth 3Y32.01%
GM growth 5Y16.44%
COP.DE Yearly Profit, Operating, Gross MarginsCOP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

2

2. COP.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so COP is destroying value.
  • Compared to 1 year ago, COP has less shares outstanding
  • Compared to 5 years ago, COP has more shares outstanding
  • COP has a worse debt/assets ratio than last year.
COP.DE Yearly Shares OutstandingCOP.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
COP.DE Yearly Total Debt VS Total AssetsCOP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of 1.79, we must say that COP is in the distress zone and has some risk of bankruptcy.
  • COP has a Altman-Z score (1.79) which is in line with its industry peers.
  • The Debt to FCF ratio of COP is 9.74, which is on the high side as it means it would take COP, 9.74 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of COP (9.74) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 1.22 is on the high side and indicates that COP has dependencies on debt financing.
  • COP has a worse Debt to Equity ratio (1.22) than 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.22
Debt/FCF 9.74
Altman-Z 1.79
ROIC/WACC0.67
WACC5.27%
COP.DE Yearly LT Debt VS Equity VS FCFCOP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.3 Liquidity

  • COP has a Current Ratio of 1.12. This is a normal value and indicates that COP is financially healthy and should not expect problems in meeting its short term obligations.
  • COP has a worse Current ratio (1.12) than 60.00% of its industry peers.
  • A Quick Ratio of 1.09 indicates that COP should not have too much problems paying its short term obligations.
  • COP has a Quick ratio of 1.09. This is in the lower half of the industry: COP underperforms 60.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 1.09
COP.DE Yearly Current Assets VS Current LiabilitesCOP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

4

3. COP.DE Growth Analysis

3.1 Past

  • The earnings per share for COP have decreased strongly by -45.71% in the last year.
  • Measured over the past years, COP shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.58% on average per year.
  • Looking at the last year, COP shows a decrease in Revenue. The Revenue has decreased by -2.19% in the last year.
  • COP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.12% yearly.
EPS 1Y (TTM)-45.71%
EPS 3Y-20.77%
EPS 5Y-13.58%
EPS Q2Q%-40%
Revenue 1Y (TTM)-2.19%
Revenue growth 3Y4.02%
Revenue growth 5Y9.12%
Sales Q2Q%0.54%

3.2 Future

  • COP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.19% yearly.
  • Based on estimates for the next years, COP will show a small growth in Revenue. The Revenue will grow by 0.36% on average per year.
EPS Next Y1.4%
EPS Next 2Y4.91%
EPS Next 3Y9.19%
EPS Next 5YN/A
Revenue Next Year2.47%
Revenue Next 2Y2.65%
Revenue Next 3Y2.49%
Revenue Next 5Y0.36%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
COP.DE Yearly Revenue VS EstimatesCOP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
COP.DE Yearly EPS VS EstimatesCOP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2

3

4. COP.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 43.58, which means the current valuation is very expensive for COP.
  • Compared to the rest of the industry, the Price/Earnings ratio of COP is on the same level as its industry peers.
  • COP's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.79.
  • Based on the Price/Forward Earnings ratio of 12.88, the valuation of COP can be described as correct.
  • Based on the Price/Forward Earnings ratio, COP is valued a bit cheaper than the industry average as 70.00% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of COP to the average of the S&P500 Index (23.80), we can say COP is valued slightly cheaper.
Industry RankSector Rank
PE 43.58
Fwd PE 12.88
COP.DE Price Earnings VS Forward Price EarningsCOP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, COP is valued a bit cheaper than the industry average as 70.00% of the companies are valued more expensively.
  • 80.00% of the companies in the same industry are more expensive than COP, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 14.34
EV/EBITDA 9.24
COP.DE Per share dataCOP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)31.03
PEG (5Y)N/A
EPS Next 2Y4.91%
EPS Next 3Y9.19%

2

5. COP.DE Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.22%, COP is not a good candidate for dividend investing.
  • COP's Dividend Yield is comparable with the industry average which is at 2.38.
  • With a Dividend Yield of 0.22, COP pays less dividend than the S&P500 average, which is at 1.91.
Industry RankSector Rank
Dividend Yield 0.22%

5.2 History

  • The dividend of COP is nicely growing with an annual growth rate of 14.75%!
Dividend Growth(5Y)14.75%
Div Incr Years2
Div Non Decr Years3
COP.DE Yearly Dividends per shareCOP.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • 191.63% of the earnings are spent on dividend by COP. This is not a sustainable payout ratio.
  • COP's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP191.63%
EPS Next 2Y4.91%
EPS Next 3Y9.19%
COP.DE Yearly Income VS Free CF VS DividendCOP.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COP.DE Dividend Payout.COP.DE Dividend Payout, showing the Payout Ratio.COP.DE Dividend Payout.PayoutRetained Earnings

COP.DE Fundamentals: All Metrics, Ratios and Statistics

COMPUGROUP MEDICAL SE & CO K

FRA:COP (6/24/2025, 7:00:00 PM)

22.66

+0.24 (+1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)04-30
Earnings (Next)07-31
Inst Owners13.38%
Inst Owner ChangeN/A
Ins Owners53.51%
Ins Owner ChangeN/A
Market Cap1.22B
Revenue(TTM)1.16B
Net Income(TTM)27.00M
Analysts56.67
Price Target21.32 (-5.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.22%
Yearly Dividend1
Dividend Growth(5Y)14.75%
DP191.63%
Div Incr Years2
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 43.58
Fwd PE 12.88
P/S 1.05
P/FCF 14.34
P/OCF 8.46
P/B 1.87
P/tB N/A
EV/EBITDA 9.24
EPS(TTM)0.52
EY2.29%
EPS(NY)1.76
Fwd EY7.76%
FCF(TTM)1.58
FCFY6.97%
OCF(TTM)2.68
OCFY11.82%
SpS21.51
BVpS12.12
TBVpS-12.86
PEG (NY)31.03
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.34%
ROE 4.15%
ROCE 5.85%
ROIC 3.53%
ROICexc 3.83%
ROICexgc 41.76%
OM 8.13%
PM (TTM) 2.34%
GM 83.85%
FCFM 7.35%
ROA(3y)2.65%
ROA(5y)3.3%
ROE(3y)7.71%
ROE(5y)9.17%
ROIC(3y)4.07%
ROIC(5y)4.45%
ROICexc(3y)4.31%
ROICexc(5y)4.74%
ROICexgc(3y)36.56%
ROICexgc(5y)51.39%
ROCE(3y)6.74%
ROCE(5y)7.38%
ROICexgc growth 3Y-23.91%
ROICexgc growth 5Y-9.04%
ROICexc growth 3Y-4.3%
ROICexc growth 5Y-14.26%
OM growth 3Y-2.61%
OM growth 5Y-10.29%
PM growth 3Y-23.61%
PM growth 5Y-19.42%
GM growth 3Y32.01%
GM growth 5Y16.44%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 1.22
Debt/FCF 9.74
Debt/EBITDA 3.86
Cap/Depr 52.61%
Cap/Sales 5.11%
Interest Coverage 2.54
Cash Conversion 69.81%
Profit Quality 314.42%
Current Ratio 1.12
Quick Ratio 1.09
Altman-Z 1.79
F-Score6
WACC5.27%
ROIC/WACC0.67
Cap/Depr(3y)60.99%
Cap/Depr(5y)64.22%
Cap/Sales(3y)5.98%
Cap/Sales(5y)6.31%
Profit Quality(3y)175.79%
Profit Quality(5y)158.42%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.71%
EPS 3Y-20.77%
EPS 5Y-13.58%
EPS Q2Q%-40%
EPS Next Y1.4%
EPS Next 2Y4.91%
EPS Next 3Y9.19%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.19%
Revenue growth 3Y4.02%
Revenue growth 5Y9.12%
Sales Q2Q%0.54%
Revenue Next Year2.47%
Revenue Next 2Y2.65%
Revenue Next 3Y2.49%
Revenue Next 5Y0.36%
EBIT growth 1Y-18.88%
EBIT growth 3Y1.31%
EBIT growth 5Y-2.11%
EBIT Next Year77.58%
EBIT Next 3Y24.98%
EBIT Next 5Y17.79%
FCF growth 1Y3.01%
FCF growth 3Y-11.08%
FCF growth 5Y-0.24%
OCF growth 1Y-8.49%
OCF growth 3Y-7.96%
OCF growth 5Y3.13%

COMPUGROUP MEDICAL SE & CO K / COP.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of COMPUGROUP MEDICAL SE & CO K (COP.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to COP.DE.


Can you provide the valuation status for COMPUGROUP MEDICAL SE & CO K?

ChartMill assigns a valuation rating of 3 / 10 to COMPUGROUP MEDICAL SE & CO K (COP.DE). This can be considered as Overvalued.


How profitable is COMPUGROUP MEDICAL SE & CO K (COP.DE) stock?

COMPUGROUP MEDICAL SE & CO K (COP.DE) has a profitability rating of 4 / 10.


What is the earnings growth outlook for COMPUGROUP MEDICAL SE & CO K?

The Earnings per Share (EPS) of COMPUGROUP MEDICAL SE & CO K (COP.DE) is expected to grow by 1.4% in the next year.


Can you provide the dividend sustainability for COP stock?

The dividend rating of COMPUGROUP MEDICAL SE & CO K (COP.DE) is 2 / 10 and the dividend payout ratio is 191.63%.